Jove
Visualize
Contact Us

Related Experiment Videos

Fludrocortisone therapy for persistent hyperkalaemia.

S J H Dobbin1, J R Petrie1, M E J Lean1

  • 1Department of Diabetes and Endocrinology, Glasgow Royal Infirmary, Glasgow, UK.

Diabetic Medicine : a Journal of the British Diabetic Association
|April 5, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of the diabetes remission clinical trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow-up.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach.

Obesity pillars·2026
Same author

Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.

Heart (British Cardiac Society)·2025
Same author

Heterogeneous metabolic response of endothelial cells from different vascular beds to experimental hyperglycaemia and metformin.

The Journal of physiology·2025
Same author

Clinical utility of liver function tests for resolution of metabolic dysfunction-associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial.

Diabetic medicine : a journal of the British Diabetic Association·2024
Same author

'I have been all in, I have been all out and I have been everything in-between': A 2-year longitudinal qualitative study of weight loss maintenance.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2020
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Fludrocortisone effectively treated recurrent hyperkalemia in a patient with Type 4 renal tubular acidosis and diabetes. This novel approach stabilized renal function when conventional methods failed, offering a new therapeutic option.

Area of Science:

  • Nephrology
  • Endocrinology
  • Internal Medicine

Background:

  • Type 4 renal tubular acidosis (RTA) is characterized by hyperkalemia, often linked to diabetes and specific medications.
  • Management of hyperkalemia in Type 4 RTA can be challenging, especially in patients with complex comorbidities.

Observation:

  • A 55-year-old woman with Type 2 diabetes and renal failure presented with recurrent hyperkalemia and deteriorating renal function.
  • Despite conventional treatments, her condition persisted, complicated by sepsis and poor venous access.
  • Fludrocortisone was initiated after 69 days of hospitalization, leading to stabilization of serum potassium and renal function.

Findings:

  • Following fludrocortisone administration, the patient's serum potassium normalized, and her estimated glomerular filtration rate (eGFR) improved.

Related Experiment Videos

  • She was discharged and remained stable for over six months, demonstrating sustained efficacy of fludrocortisone.
  • This case highlights the potential of fludrocortisone in managing refractory hyperkalemia associated with Type 4 RTA.

    • Implications:

    • Fludrocortisone may represent a novel therapeutic strategy for difficult cases of Type 4 RTA with hyperkalemia.
    • Further research is warranted to explore the broader application of fludrocortisone in similar patient populations.
    • This case contributes to the limited evidence base for fludrocortisone use in this specific clinical context.